Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FLGT vs VCYT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FLGT Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 4–6 Matrix Metrics)

FLGT Overall Winner 6-Pillar Tally: FLGT 3 – 3 VCYT Matrix Metrics: FLGT 4 – 6 VCYT

As of Nov 16, 2026, Fulgent Genetics, Inc. (FLGT) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). FLGT carries a Unified Composite Score of 33.3/100 (SELL) at $24.07 (7.7x Forward P/E, -37.1% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).

  • Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. FLGT 33.3/100 SELL), FLGT captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-37.1% vs. 15.0% operating margin) and revenue trajectory (+7.5% vs. +15.1% YoY).
  • Technical & Structure Timing Caution: FLGT trades in a Markup technical trend (BREAKOUT options phase, RSI 59.0); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FLGT vs VCYT
FLGT NASDAQ Head-to-Head Winner
Fulgent Genetics, Inc. Common Stock
Services-Medical Laboratories
$24.07
-2.37% 1D
Market Cap $689.0M
TTM Revenue $330M
Forward P/E 7.7x
Beta / 30D Vol 1.10β · 110% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 50.0 Fund 32.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.8% over 20 days), RSI 59
RSI-14: 59.0 · SMA20: $21.86 · SMA50: $21.47
VCYT NASDAQ
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79

6-Pillar Scorecard Institutional Category Breakdown (FLGT 3 – 3 VCYT)

Columns: Metric · FLGT · VCYT
1. Valuation Multiples FLGT
Forward P/E 7.7x 15.3x
Trailing P/E 7.7x 15.8x
PEG Ratio 1.32x N/M
EV / Revenue 1.9x 3.1x
2. Growth & Scale VCYT
Revenue Growth (YoY) +7.5% +15.1%
Earnings Growth (YoY) -98.6% +58.3%
TTM Revenue (USD) $330M $582M
Market Cap $689.0M $2.0B
3. Profitability & Quality VCYT
Gross Margin 33.8% 74.2%
Operating Margin -37.1% 15.0%
Net Profit Margin -27.5% 21.8%
Return on Equity (ROE) -8.7% 9.4%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) -$1.4M $162M
Cash Flow Margin -0.4% 27.8%
Net Cash / Leverage $77M Net Cash $159M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FLGT
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 67.5% (13th %ile) 197.3% (47th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat FLGT
OpEx & R&D Intensity 70.9% of Rev ($234M) 59.2% of Rev ($344M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FLGT (4) vs VCYT (6)
Institutional Metric FLGT VCYT Criterion Row Edge
Market Capitalization
Scale
$689.0M $2.0B Larger Scale VCYT
Trailing P/E Ratio
Valuation
7.7x 15.8x Lower Multiple FLGT
Forward P/E Ratio
Valuation
7.7x 15.3x Lower Multiple FLGT
Revenue Growth (YoY)
Growth
+7.5% +15.1% Higher Growth VCYT
Operating Margin (TTM)
Profitability
-37.1% 15.0% Higher Margin VCYT
Net Profit Margin
Profitability
-27.5% 21.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
-8.7% 9.4% Higher ROE VCYT
52-Week Range Position
Momentum
60% ($13–$31) 5% ($22–$61) Stronger Trend FLGT
Beta / 30D Volatility
Risk Regime
1.10β · 110% Vol 3.01β · 199% Vol Lower Realized Risk FLGT
Unified Institutional Score
Composite Signal
33.3 / 100 (SELL) 49.1 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$330M $582M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
33.8% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.32x PEG · 1.9x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($77M Net Cash) $162M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FLGT +65.85 pp
FLGT: +21.53% · VCYT: -44.32%
3M Horizon FLGT +70.62 pp
FLGT: +29.64% · VCYT: -40.98%
6M Horizon FLGT +94.03 pp
FLGT: +51.89% · VCYT: -42.14%
1Y Horizon FLGT +21.14 pp
FLGT: -18.64% · VCYT: -39.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FLGT Revenue VCYT Revenue FLGT Op. Margin VCYT Op. Margin Margin Leader
FY2018 $20M $90M -23.7% -24.2% FLGT
FY2019 $30M $120M -1.3% -12.6% FLGT
FY2020 $420M $120M 68.8% -30.1% FLGT
FY2021 $990M $220M 68.1% -37.3% FLGT
FY2022 $620M $300M 28.8% -13.9% FLGT
FY2023 $290M $360M -67.6% -23.8% VCYT
FY2024 $280M $450M -26.1% 3.6% VCYT
FY2025 $320M $520M -28.2% 11.2% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FLGT BREAKOUT
94d in phase · OBV NEUTRAL
Current IV 67.5%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact FLGT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FLGT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $689.0M market capitalization and -37.1% operating margin.
OpEx & R&D Reinvestment 70.9% of Rev ($234M)
90D Engineering Disclosures 0 Published
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published

Investor FAQ FLGT vs VCYT Key Questions & Quantitative Answers

As of Nov 16, 2026, Fulgent Genetics, Inc. (FLGT) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). FLGT carries a Unified Composite Score of 33.3/100 (SELL) at $24.07 (7.7x Forward P/E, -37.1% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. FLGT 33.3/100 SELL), FLGT captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-37.1% vs. 15.0% operating margin) and revenue trajectory (+7.5% vs. +15.1% YoY). Technical & Structure Timing Caution: FLGT trades in a Markup technical trend (BREAKOUT options phase, RSI 59.0); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: FLGT posts +7.5% YoY revenue growth and -98.6% YoY earnings growth on $330M TTM revenue (33.8% gross margin, -37.1% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FLGT cumulative revenue shifted +1500.0% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, FLGT deploys 70.9% of Rev ($234M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.

FLGT screens cheaper on headline valuation multiples. FLGT trades at 7.7x Forward P/E, 7.7x Trailing P/E, 1.32x PEG, and 1.9x EV/Revenue (-0.4% FCF margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FLGT (-8.7% ROE) versus VCYT (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, FLGT carries 67.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.10β · 110% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.